Kairos Pharma, LTD. — Investor Relations & Filings
Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics. The company's primary focus is on overcoming key hurdles in cancer treatment, specifically drug resistance and immune suppression. Its lead product candidate, ENV105, is an antibody that targets the CD105 protein to reverse resistance to existing cancer drugs. ENV105 is in mid-stage clinical trials for prostate cancer and early-stage trials for lung cancer. In addition, Kairos is developing a pipeline of immunotherapies designed to reverse cancer-induced immune suppression. This includes KROS101, a small molecule to enhance T cell activity, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma, for which an Investigational New Drug (IND) application has been cleared.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS | 2026-05-22 | English | |
| DEF 14A | 2026-05-22 | English | |
| 8-K | 2026-05-18 | English | |
| 10-Q - Kairos Pharma, LTD. (0001962011) (Filer) | 2026-05-13 | English | |
| 424B3 - Kairos Pharma, LTD. (0001962011) (Filer) | 2026-04-01 | English | |
| 424B3 - Kairos Pharma, LTD. (0001962011) (Filer) | 2026-04-01 | English |
Browse filings by year
4 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 46858929 | ARS | 2026-05-22 | English | ||
| 46859112 | DEF 14A | 2026-05-22 | English | ||
| 46385140 | 8-K | 2026-05-18 | English | ||
| 45772712 | 10-Q - Kairos Pharma, LTD. (0001962011) (Filer) | 2026-05-13 | English | ||
| 33150127 | 424B3 - Kairos Pharma, LTD. (0001962011) (Filer) | 2026-04-01 | English | ||
| 33150126 | 424B3 - Kairos Pharma, LTD. (0001962011) (Filer) | 2026-04-01 | English | ||
| 32900692 | 8-K - KAIROS PHARMA, LTD. (0001962011) (Filer) | 2026-03-02 | English | ||
| 32900691 | 8-K - KAIROS PHARMA, LTD. (0001962011) (Filer) | 2026-02-26 | English | ||
| 13637369 | Regulatory Filings 2026 | 2026-01-26 | English | ||
| 13637370 | S-3 | 2026-01-13 | English | ||
|
2025
5 filings
| |||||
| 13637371 | 4 | 2025-12-30 | English | ||
| 13637372 | 4 | 2025-12-23 | English | ||
| 13637373 | 4 | 2025-11-27 | English | ||
| 13637375 | 4 | 2025-11-26 | English | ||
| 13637374 | 4 | 2025-11-26 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Kairos Pharma, LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34903/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34903 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34903 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34903 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34903}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Kairos Pharma, LTD. (id: 34903)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.